Tumors are comprised of both cancer cells and surrounding stromal components. As an
essential part of the tumor microenvironment, the tumor stroma is highly dynamic …

Lung cancer remains a leading cause of cancer related mortality worldwide. Despite
numerous advances in treatments over the past decade, non-small cell lung cancer …

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …

Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …

Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …

Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …

Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in
the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents …

Highlights•A virtual consensus on the management of EGFR-mutant NSCLC was organized
by the ESMO, including 34 experts from 18 countries.•The experts compiled …

The vascular endothelial growth factor (VEGF) pathway has been recognized as a key
mediator of angiogenesis to support tumorigenesis. Multiple therapeutic agents targeting …

PURPOSE In the treatment of non–small-cell lung cancer (NSCLC) with a driver mutation,
the role of anti–PD-(L) 1 antibody after tyrosine kinase inhibitor (TKI) remains unclear. This …